Filing Flows › Novo Nordisk A S (NVO) › Free cash flow
Novo Nordisk A S (NVO) free cash flow by quarter
Novo Nordisk A S' free cash flow was $28.5B in Q3 2026 (third quarter 2026), -33% from Q2 2026. Over the last 5 quarters it ranged from $12.8B (Q1 2026) to $42.5B (Q2 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $28.5B | -33% | -12% |
| Q2 2026 | $42.5B | +233% | +63% |
| Q1 2026 | $12.8B | -61% | — |
| Q3 2025 | $32.5B | +24% | — |
| Q2 2025 | $26.1B | — | — |
Q3 2026 at a glance
Novo Nordisk A S, Q3 2026: revenue $79.2B (+6% year over year), operating margin 29.1%, net earnings $16.7B, operating cash flow $41.7B. The chart follows the revenue to costs, profit and cash.
Questions
What is Novo Nordisk A S' free cash flow?
Novo Nordisk A S' free cash flow was $28.5B in Q3 2026 (third quarter 2026), -33% from Q2 2026.
How has Novo Nordisk A S' free cash flow changed?
Over the last 5 quarters it ranged from $12.8B (Q1 2026) to $42.5B (Q2 2026).